Key result
Adult patients with localized Ewing sarcoma had a significantly longer median progression-free survival compared to those with metastatic disease (72 months vs 10 months, p=0.005).
Why the study?
What are the survival outcomes and prognostic factors for Ewing sarcoma in adult patients?
Observational (n=26)
No
What are the survival outcomes and prognostic factors for Ewing sarcoma in adult patients?
In adult patients with Ewing sarcoma, localized disease in the extremities and age under 30 are associated with a favorable prognosis, while metastatic disease has poor survival outcomes.
Answers are grounded in this paper and cite their sources.
Metastatic disease signals poor survival in adult Ewing sarcoma; leaves open optimal systemic approaches pending prospective data.
BACKGROUND: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis. MATERIALS AND METHODS: The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively. RESULTS: The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis. CONCLUSIONS: Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.
No takes yet. Share an insight, caveat, or question.
ŞEKER et al. (2014) conducted an observational in Ewing Sarcoma (n=26). Localized disease vs. Metastatic disease was evaluated on Median progression-free survival (months) (p=0.005). Adult patients with localized Ewing sarcoma had a significantly longer median progression-free survival compared to those with metastatic disease (72 months vs 10 months, p=0.005).
Synapse has enriched 10 related papers. Consider them for comparative context: